Intracranial stimulation for brain cancer-The case for implantable, intracranial tumor treating fields

David J Segar¹, Joshua D Bernstock^{2

3

4}, Sumientra Rampersad^{5

6}, Wenya Linda Bi², Omar Arnaout², Gregory K Friedman⁷, E Antonio Chiocca²

Affiliations

¹ Department of Neurosurgery, University of California, San Francisco, California, USA.
² Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Neurosurgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
⁵ Department of Physics, University of Massachusetts, Boston, Massachusetts, USA.
⁶ Department of Electrical and Computer Engineering, Northeastern University, Boston, Massachusetts, USA.
⁷ Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Review

David J Segar et al. Neurooncol Adv. 2023.

. 2023 Aug 19;5(1):vdad100.

doi: 10.1093/noajnl/vdad100. eCollection 2023 Jan-Dec.

David J Segar¹, Joshua D Bernstock^{2

3

4}, Sumientra Rampersad^{5

6}, Wenya Linda Bi², Omar Arnaout², Gregory K Friedman⁷, E Antonio Chiocca²

¹ Department of Neurosurgery, University of California, San Francisco, California, USA.
² Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Neurosurgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
⁵ Department of Physics, University of Massachusetts, Boston, Massachusetts, USA.
⁶ Department of Electrical and Computer Engineering, Northeastern University, Boston, Massachusetts, USA.
⁷ Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.

No abstract available

Figures

1. Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 2021;9(3):324. - PMC - PubMed
1. Lassman AB, Joanta-Gomez AE, Pan PC, Wick W. Current usage of tumor treating fields for glioblastoma. Neuro-Oncol Adv. 2020;2(1):vdaa069. - PMC - PubMed
1. Segar DJ, Bernstock JD, Arnaout O, et al. . Modeling of intracranial tumor treating fields for the treatment of complex high-grade gliomas. Sci Rep. 2023;13(1):1–11. - PMC - PubMed
1. Ballo MT, Urman N, Lavy-Shahaf G, et al. . Correlation of tumor treating fields dosimetry to survival outcomes in newly diagnosed glioblastoma: A large-scale numerical simulation-based analysis of data from the phase 3 EF-14 Randomized Trial. Int J Radiat Oncol Biol Phys. 2019;104(5):1106–1113. - PubMed
1. Berkelmann L, Bader A, Meshksar S, et al. . Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis. Sci Rep. 2019;9(1):7362. - PMC - PubMed